Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 11 December 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Polymorphisms that are associated with drug-induced liver injury from statins

The most recent issue of Gastroenterology examines the association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study.

News image

Dr Ann Daly and colleagues from the United Kingdom performed a genome-wide association study (GWAS) to identify genetic risk factors for drug-induced liver injury from licensed drugs without previously reported genetic risk factors.

The research team performed a GWAS of 862 persons with drug-induced liver injury, and 10,588 population-matched controls. 

The first set of cases was recruited before 2009 in Europe, and the United States. 

The second set of cases were identified from 2009 through 2013 from international collaborative studies performed in Europe, the United States, and South America. 

For the GWAS, the research team included only cases with patients of European ancestry associated with a particular drug. 

The polymorphism on chromosome 2 was associated with cholestatic and mixed drug-induced liver injury
Gastroenterology
The researchers used DNA samples from all subjects to analyze HLA genes and single nucleotide polymorphisms. 

After the discovery analysis was concluded, the team validated their findings using data from 283 European patients with diagnosis of drug-induced liver injury associated with various drugs.

The team associated drug-induced liver injury with rs114577328, and with rs72631567 on chromosome 2. 

The researchers found that the association with A*33:01 was mediated by large effects for terbinafine-, fenofibrate-, and ticlopidine-related drug-induced liver injury. 

The variant on chromosome 2 was associated with drug-induced liver injury from a variety of drugs. 

Further phenotypic analysis indicated that the association between drug-induced liver injury, and A*33:01 was significant genome wide for cholestatic and mixed drug-induced liver injury, but not for hepatocellular drug-induced liver injury.

The team noted that the polymorphism on chromosome 2 was associated with cholestatic and mixed drug-induced liver injury as well as hepatocellular drug-induced liver injury. 

The researchers identified an association between rs28521457, and only hepatocellular drug-induced liver injury. 

The team did not associate any specific drug classes with genetic polymorphisms, except for statin-associated drug-induced liver injury, which was associated with rs116561224 on chromosome 18. 

The researchers validated the association between A*33:01 terbinafine- and sertraline-induced drug-induced liver injury. 

The team could not validate the association between drug-induced liver injury and rs72631567, rs28521457, or rs116561224.

Dr Daly's team concludes, "In a GWAS of persons of European descent with drug-induced liver injury, we associated HLA-A*33:01 with drug-induced liver injury due to terbinafine and possibly fenofibrate and ticlopidine."

"We identified polymorphisms that appear to be associated with drug-induced liver injury from statins, as well as 2 non-drug-specific risk factors."

Gastroenterol 2017: 152(5): 1078–1089 
10 April 2017

Go to top of page Email this page Email this page to a colleague

 06 December 2017 
Preventing hepatic encephalopathy-related readmissions
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure
 05 December 2017 
Childhood obesity into adulthood
 05 December 2017 
CT imaging for acute diverticulitis
 05 December 2017 
Thiopurines and colorectal cancer in IBD
 04 December 2017 
Neoadjuvant chemoradiation for locally advanced rectal cancer
 04 December 2017 
Physical activity and Barrett’s esophagus
 04 December 2017 
Alcohol abstinence and alcoholic hepatitis
 01 December 2017 
Therapeutic drug monitoring in IBD
 01 December 2017 
Insulin therapy and liver cancer among diabetics
 01 December 2017 
Family burden of pediatric Crohn's in the USA
 30 November 2017 
Anastomotic leak after repeat intestinal resection in Crohn’s
 30 November 2017 
Oral capsule– vs colonoscopy-delivered fecal microbiota transplant
 30 November 2017 
Sessile serrated polyps and H. pylori in the USA
 29 November 2017 
Medical cannabinoid legalization policy and vomiting
 29 November 2017 
Predicting mortality after colectomy for C. diff
 29 November 2017 
Obesity and cancer risk
 28 November 2017 
Celiac disease screening in adult first-degree relatives
 28 November 2017 
Electronic health record alert in primary care in Hep C
 28 November 2017 
Surgical treatment delays and colon cancer survival
 27 November 2017 
Challenges in measuring the affordability of US health care
 27 November 2017 
Questionnaire fore chronic constipation
 27 November 2017 
Early readmission in IBD patients
 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Predicting microscopic colitis
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Environmental factors and IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us